Comparison
Lanreotid vs. Linaclotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
108736-35-2
851199-59-2
Molecular weight
1096.34 g/mol
1526.74 g/mol
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Lanreotid
Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
0
of which in humans
1
0
Effects recorded
2
2
Open conflicts
1
0
Documented adverse events
2
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Lanreotid and Linaclotid?
- Lanreotid is classified as "Research other", while Linaclotid is classified as "Research other". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lanreotid or Linaclotid?
- The highest available evidence level is "Human RCT" for Lanreotid and "Human RCT" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lanreotid and Linaclotid in Germany and the United States?
- Germany: Lanreotid — Prescription, Linaclotid — Prescription. United States: Lanreotid — Prescription, Linaclotid — Prescription. These are factual summaries with source and review date on the individual pages.